Engflag

Clonotril PLUS

Quick links to important sections

Clonotril PLUS

Clonotril PLUS_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clonotril PLUS

Quick Facts: Clonotril PLUS

Property Description
Active Ingredients Clonazepam and Escitalopram
Form Oral Tablet (Fixed-dose combination)
Pharmacological Class Benzodiazepine and Selective Serotonin Reuptake Inhibitor (SSRI)
Common Use Support for co-existing anxiety and mood disorders
Origin Synthetic

What Type of Medicine is Clonotril PLUS?

Clonotril PLUS is a synthetic, fixed-dose combination product categorized as a high-value prescription medicine intended for the management of complex emotional states. This formulation is prepared as an oral tablet that structurally unites two distinct pharmacological agents to ensure simultaneous delivery. The active ingredients are Clonazepam, a drug classified as a Benzodiazepine, and Escitalopram, an agent belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class.

This dual-entity nature differentiates the formulation from monotherapies. The structural combination is clinically recognized for providing simultaneous relief and chemical support, a strategy that is particularly relevant for adult patients experiencing co-existing anxiety and mood disorders. Other popular generic formulations with this composition include Nexito Plus and Stalopam Plus.

Key Components and Pharmacological Action

The medication integrates Clonazepam, which functions as the rapid-onset agent, and Escitalopram, which serves as the sustained-action agent. Clonazepam provides a direct calming effect by enhancing Gamma-Aminobutyric Acid (GABA) activity in the brain. Conversely, Escitalopram gradually works over time to stabilize mood regulation by inhibiting the re-uptake of the neurotransmitter Serotonin (5-HT).

The therapeutic rationale for combining anxiolytics and antidepressants involves managing emotional disorders and utilizing combinations like this to improve overall stability during the initial phase of treatment. The general purpose of this combination is to achieve a synergistic effect, managing both the immediate debilitating symptoms and the chronic underlying factors contributing to persistent emotional distress.

Is Clonotril PLUS a Single Drug or a Combination?

Clonotril PLUS is definitively a combination drug, representing an integration of two pharmacologically different, individually effective chemical substances into a single dosage form. This contrasts with a single-entity product that contains only one active ingredient. The fixed combination is a key differentiator, designed to streamline the support for patients by providing two distinct, complementary actions through one oral dosage form.

Regulatory References

  1. Benzodiazepine (StatPearls)
  2. Clonazepam mechanism (StatPearls)

What side effects are possible with Clonotril PLUS?

Possible side effects and safety information

The safety profile for this fixed-dose combination, containing Clonazepam (Benzodiazepine) and Escitalopram (SSRI), is derived from the established adverse reaction classifications documented in official regulatory labeling.

Common Adverse Reactions and Systemic Effects

Adverse effects officially classified as common in clinical studies may include central nervous system (CNS) effects such as somnolence (drowsiness), dizziness, and fatigue. Gastrointestinal effects like nausea and dry mouth are also frequently documented. Additionally, decreased libido and ejaculatory disorder are common reactions attributed to the SSRI component.

These common effects are often categorized across several System-Organ Classes, including the Nervous System, Psychiatric Disorders, and Gastrointestinal Disorders, reflecting the dual action of the medicine.

Serious Adverse Reactions and Regulatory Warnings

Regulatory documents highlight several serious adverse reactions requiring close attention. The use of this medicine is associated with a risk of Serotonin Syndrome, a potentially severe reaction reported with SSRIs. Furthermore, the official labeling includes warnings regarding the potential for suicidal thoughts and behavior, particularly during the initial months of therapy or following dose changes, a risk common to antidepressants.

Rare but serious effects, such as QT interval prolongation (a heart rhythm disturbance) and activation of mania or hypomania, have also been documented in regulatory sources.

Population and Time-Related Safety

Specific population safety considerations exist, including a contraindication for patients with significant liver disease due to the metabolic profile of Clonazepam. Older adults are advised a reduced dosage due to increased sensitivity and risks like hyponatremia (low sodium levels). The highest risk for certain events, like clinical worsening, is officially noted to occur during the initial few months of treatment.

Overdose and Emergency Response

Overdose of Clonotril PLUS combines the documented risks of CNS depression from the Clonazepam component with the serotonergic and cardiotoxic potential of the Escitalopram component. Manifestations listed in regulatory documents often include signs such as drowsiness, confusion, impaired coordination (ataxia), slurred speech, alongside autonomic changes like tachycardia and profuse sweating.

Severe or life-threatening outcomes documented in regulatory sources include respiratory depression, coma, seizures, and the risk of Serotonin Toxicity or QTc prolongation. These severe events, particularly when resulting from co-ingestion with other substances, define the high-level risk of the combination.

Immediate action is required upon any suspicion of overdose. Regulatory guidance mandates to seek immediate medical attention and contact emergency services immediately if the person has collapsed, is experiencing difficulty breathing, or cannot be awakened.

Management procedures are defined as symptomatic and supportive treatment within a hospital setting. Continuous observation and mandatory ECG monitoring are essential for managing the documented cardiac risks. While Flumazenil, a specific antagonist, is documented as being available for the benzodiazepine component, there is no specific antidote known for Escitalopram overdose. Regulatory labeling notes that elderly patients are more susceptible to severe manifestations, including confusion and hyponatremia.

Therapeutic Uses of Clonotril PLUS

What Clonotril PLUS Treats: Main Uses and Benefits

This combination is primarily used to address the complex challenge of co-occurring anxiety and mood disorders, specifically when Major Depressive Disorder is complicated by significant anxiety. This strategy utilizes the combination for the symptomatic management of patients with these comorbidities.

It is used for managing symptoms related to conditions, including Panic Disorder, Generalized Anxiety Disorder, and Major Depressive Disorder with an anxiety component. The formulation may be applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load where persistent worry, tension, and an underlying state of sadness manifest together.

The medication is commonly used to help with the intensity of sudden panic attacks, symptoms of increased neurological or muscular activity, and neurovegetative disruptions like insomnia. This supportive action helps in maintaining a sense of daily stability and supports patients during episodes of heightened discomfort.

“The combination is relevant for easing symptoms associated with both acute or episodic changes and persistent emotional conditions.”

Quick Fact: Relief for Co-morbid Symptoms
Symptom Domains Acute anxiety, panic episodes, chronic tension, disturbed sleep, persistent sadness
Clinical Context Managing complex dual diagnoses (anxiety + mood disorder)
Key Benefit Contributes to maintaining a sense of daily stability and easing overall symptom load

Eligibility and Restrictions for Use

Who Can and Cannot Use Clonotril PLUS?

Eligibility for Clonotril PLUS (Clonazepam and Escitalopram) is defined by mandatory restrictions outlined in official regulatory labeling. This medicine is primarily intended for adult patients with co-occurring anxiety and mood disorders. Several conditions and patient groups are explicitly designated as ineligible or require strict caution.

Absolute Contraindications (Must Not Use)

Clonotril PLUS is formally contraindicated for patients with:

  • Significant Liver Disease or severe hepatic insufficiency.
  • Acute Narrow Angle Glaucoma.
  • Severe Respiratory Conditions (e.g., sleep apnoea, severe respiratory insufficiency).
  • Known QT Interval Prolongation or congenital long QT syndrome.
  • Hypersensitivity to any benzodiazepine or SSRI component.
  • Concomitant treatment with certain MAO-inhibitors.

Conditional Use and Restrictions

  • Age: Use is not recommended in pediatric patients (under 18) as safety is not established. Older adults (65+) require caution and close monitoring.
  • Physiological Status: Use is not recommended during pregnancy or breastfeeding.
  • Comorbidities: Caution is required for patients with renal impairment, a history of mania/hypomania, or unstable epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Clonotril PLUS, a combination of Clonazepam and Escitalopram, is defined by regulatory restrictions across pharmacokinetic and pharmacodynamic domains.

Contraindicated Combinations

Certain combinations are explicitly prohibited in regulatory labeling due to the high risk of serious adverse events. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of Serotonin Syndrome. Similarly, the combination with Pimozide is contraindicated due to the documented risk of QT interval prolongation.

Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substances (Official Documentation) Required Constraint/Outcome
Additive CNS Depression Opioid Analgesics, Alcohol, other CNS depressants Formal warnings against use; risk of profound sedation and respiratory depression.
Serotonergic Load Other serotonergic drugs, St. John’s wort Increased official risk of Serotonin Syndrome.
Pharmacokinetic (Exposure) CYP2D6 Substrates, CYP3A Inducers Escitalopram inhibits CYP2D6, increasing exposure of co-administered drugs like Desipramine. CYP3A inducers reduce Clonazepam plasma levels.
Hemostatic Risk NSAIDs, Warfarin Increased risk of abnormal bleeding due to interference with platelet aggregation.

Timing and Population Restrictions

A mandatory 14-day washout period is required when switching between Clonotril PLUS and an MAOI. Furthermore, Clonazepam is contraindicated in patients with significant liver disease due to documented potential for impaired drug elimination.

Mechanism of Action

Modulation of CNS Neurotransmitter Receptors

Clonotril PLUS acts through two distinct molecular pathways. The first component, a benzodiazepine derivative, binds non-competitively to a specific allosteric site located on the GABA A receptor complex. This molecular interaction causes an allosteric change in the receptor's conformation, which subsequently increases the receptor's affinity for the inhibitory neurotransmitter GABA. The second component acts as a selective serotonin reuptake inhibitor (SSRI), preventing the reuptake of serotonin (5-HT) by the presynaptic neuron.

Intracellular Ion Flow and System-Level Consequence

The increased GABA A affinity leads to more frequent opening of the GABA-gated chloride ion channel. This action facilitates the influx of chloride ions ( Cl^-) into the postsynaptic neuron, causing membrane hyperpolarization. Hyperpolarization increases the threshold potential required for the neuron to fire an action potential, which results in the inhibition of neuronal excitability. Concurrently, the SSRI component prolongs the activity of 5-HT in the synaptic cleft, leading to a reduction of neural conduction frequency and the re-establishment of normal inhibitory tone across relevant neural networks.

Dosage and Administration Information

How to Use Clonotril PLUS

This section describes standard administration protocols for the combination medicine.

Administration Scope

Feature Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule Typically one tablet once daily (one or two tablets may be used for initial therapy) as prescribed by a physician.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements Swallow the tablet whole with a glass of water; do not chew, crush, or break the tablet.
Age/Condition Rules Lower doses or careful dose adjustment may be required for elderly patients and those with liver or kidney impairment.

Missed Dose and Discontinuation

Missed Dose Rules: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the patient should resume the regular dosing schedule. A double dose must not be taken to make up for a missed one.

Special Procedural Conditions: The medicine must not be stopped suddenly. Discontinuation requires the dose to be gradually reduced over a period of several weeks or months, as directed by a healthcare professional, to prevent the occurrence of withdrawal symptoms.

Procedural Summary

The standard instructions establish a precise protocol for using this medication that mandates daily oral administration of the tablet, which must be swallowed intact. The entire course of treatment must be followed, and any decision to stop the medicine, even if symptoms improve, must involve a doctor-managed, gradual dose taper.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Anxiety and Mood

Research has explored the impact of Clonotril PLUS (a combination of clonazepam and escitalopram) on measures of anxiety and mood disorders. Studies focused primarily on individuals experiencing conditions such as Generalized Anxiety Disorder (GAD) and Panic Disorder (PD), often with co-occurring symptoms of depression.

  • One randomized, open-label trial evaluated the use of clonazepam versus the antidepressant paroxetine for Panic Disorder. The study reported greater clinical improvements and fewer weekly panic attacks for the clonazepam group after eight weeks of treatment.
  • An eight-week study on adults with major depression assessed the use of clonazepam augmentation with fluoxetine versus fluoxetine alone. The research observed greater improvement in depression rating scales during the first three weeks of combined treatment.

Dosage and Safety Profile

Research evaluated a variety of doses for the individual components of Clonotril PLUS, depending on the specific disorder studied.

  • The most commonly reported adverse events for the combination included central nervous system effects such as drowsiness, dizziness, and fatigue, as well as gastrointestinal upset and sexual dysfunction.
  • Due to the inclusion of clonazepam, studies and regulatory warnings highlight the risk of physical dependence with continued use and the potential for serious respiratory depression when used concurrently with opioids.

Combination Therapy Studies

Research has examined the strategy of using the two components of Clonotril PLUS together, particularly at the start of treatment with an antidepressant, which can take several weeks to reach its full effect.

  • A study on panic disorder compared continuous combination therapy (antidepressant plus clonazepam) to antidepressant monotherapy. The combined treatment was associated with a more rapid response during the initial weeks of treatment, but the long-term outcomes at the study endpoint were similar across all groups.

Frequently Asked Questions (FAQ)

Common questions about Clonotril PLUS (FAQ)

Q: What is Clonotril PLUS used for, specifically?

Clonotril PLUS is a combination medication approved for the treatment of essential hypertension, which is high blood pressure with no identifiable cause. According to regulatory documents, it is typically used when treatment with a single component (clonidine or chlorthalidone) has not provided adequate blood pressure control.

Q: Is Clonotril PLUS a diuretic (water pill)?

Yes, one of the active ingredients in Clonotril PLUS is chlorthalidone, which is a type of diuretic, often described as a 'water pill.' Official information states that the diuretic component helps the body eliminate excess salt and water, which contributes to lowering blood pressure when combined with the other component, clonidine.

Q: Does Clonotril PLUS affect the central nervous system?

Yes, the action of Clonotril PLUS involves effects on the central nervous system. Regulatory sources indicate that clonidine, one of the active ingredients, works by stimulating specific receptors in the brain to decrease the impulses that cause blood vessels to constrict. This action contributes to the overall effect of decreasing blood pressure.

Q: Can I stop taking Clonotril PLUS suddenly if I feel better?

Official product information cautions against suddenly stopping Clonotril PLUS treatment. Abrupt discontinuation can potentially lead to a rapid increase in blood pressure, known as rebound hypertension. The official guidance states that if discontinuation is necessary, it is generally carried out gradually under the direction of a healthcare professional.

Q: How long does it take for Clonotril PLUS to start working to lower blood pressure?

Regulatory information indicates that the initial blood pressure-lowering effect of Clonotril PLUS may be observed shortly after the first dose. However, achieving the full therapeutic benefit and stable long-term blood pressure control may take several weeks as the body adjusts to the medication.

Q: Does this medication cause drowsiness or affect alertness?

The official product information lists drowsiness (somnolence) and sedation among the very common side effects associated with Clonotril PLUS. The drug's influence on the central nervous system can affect alertness and reaction time. The product label includes warnings about the potential risk when driving or operating machinery due to these effects.

Q: Is it safe to drink alcohol while on Clonotril PLUS?

According to the official product information, alcohol may increase the effects of Clonotril PLUS, particularly those related to the central nervous system, such as sedation and dizziness. The combination is noted to potentially enhance these side effects. Patients are generally advised to use caution and should consult with a healthcare provider regarding alcohol use while taking this medication.

How should Clonotril PLUS be stored and disposed of?

The official requirements for the storage and disposal of this medication, which contains the controlled substance Clonazepam, are defined by regulatory documents.

Storage & Disposal Scope

Labeled Storage Temperature Requirements Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Light/Moisture Protection Requirements Keep in a cool, dry place and away from excess heat and moisture (e.g., not in the bathroom).
Packaging-Related Storage Rules Keep this medication in its original container and ensure it is tightly closed.
Child-Protection Storage Requirements Store out of the sight and reach of children and in a secure, safe location due to the controlled substance component.
Disposal Instructions The preferred method is a drug take-back program. Otherwise, follow the FDA guidance for controlled substances: mix the tablets with an unpalatable substance (like dirt) and seal the mixture before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clonotril PLUS found in:

A-Z Index: